» Articles » PMID: 34612153

LncRNA LINC00460 Takes a Stimulating Role on Hepatocellular Carcinoma Stemness Property

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2021 Oct 6
PMID 34612153
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Abundant researches have stated that long noncoding RNAs (lncRNAs) are crucial molecules in intricate progression of various cancers in terms of their influence on cell stemness. However, no research has discussed the role of LINC00460 in the stemness of hepatocellular carcinoma (HCC). RT-qPCR and western blot were utilized to respectively examine the RNA and protein levels. Aldehyde dehydrogenase 1 (ALDH1) assays and sphere formation assay were performed to detect cell stemness property in vitro and in vivo subcutaneous xenograft tumor assay was performed to detect tumor growth. Interaction between RNAs was explored by luciferase reporter assays and RNA pull-down assays. Our results showed that LINC00460 was markedly over-expressed in HCC and silencing LINC00460 impaired cell stemness. Additionally, LINC00460 knockdown curbed proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT) and drove apoptosis of HCC cells. Further, LINC00460 bound to miR-503-5p and miR-654-3p to protect t-complex 1 (TCP1) from being inhibited by miR-503-5p/miR-654-3p. Rescue experiments confirmed the effect of LINC00460/miR-503-5p/miR-654-3p/TCP1 on HCC cell stemness. In conclusion, LINC00460 aggravated cell stemness in HCC via targeting miR-503-5p/miR-654-3p and TCP1, suggesting that LINC00460 may work as a potential signature for cell stemness in HCC.[Figure: see text].

Citing Articles

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors.

Wei Y, Li Y, Chen Y, Liu P, Huang S, Zhang Y Front Oncol. 2022; 12:1026278.

PMID: 36387165 PMC: 9650078. DOI: 10.3389/fonc.2022.1026278.


A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.

Lin L, Wu X, Zhu J, Chen S, Chen Y, Lin F Comb Chem High Throughput Screen. 2022; 26(8):1503-1518.

PMID: 36165528 PMC: 10242768. DOI: 10.2174/1386207325666220926123923.

References
1.
Lo R, Leung C, Chan K, Ho D, Wong C, Lee T . Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway. Cell Death Differ. 2018; 25(8):1426-1441. PMC: 6113239. DOI: 10.1038/s41418-018-0059-x. View

2.
Zhuang R, Zhang X, Lu D, Wang J, Zhuo J, Wei X . lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling. Mol Carcinog. 2018; 58(3):366-375. DOI: 10.1002/mc.22934. View

3.
Qi X, Zhang D, Wu N, Xiao J, Wang X, Ma W . ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015; 52(10):710-8. DOI: 10.1136/jmedgenet-2015-103334. View

4.
Cheng D, Deng J, Zhang B, He X, Meng Z, Li G . LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018; 36:159-170. PMC: 6197532. DOI: 10.1016/j.ebiom.2018.08.055. View

5.
Grandhi M, Kim A, Ronnekleiv-Kelly S, Kamel I, Ghasebeh M, Pawlik T . Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016; 25(2):74-85. DOI: 10.1016/j.suronc.2016.03.002. View